Milo Vapes Global (MVG) has announced its plans to release a range of flavored tobacco products under two brands, Milo Vapor™ and Sahara Mist™, exclusively in the Middle East region in the fall of 2022.
The Global State of Tobacco Harm Reduction (GSTHR) report reveals that there are currently 85 million smokers in the Middle East, with expectations to reach 100 million by 2025. The average smoking rate in the region stands at 31.2%, with Jordan having the highest rate of 41.1% followed by Lebanon at 31.8%. Conversely, Morocco and Qatar have the lowest smoking rates at 13.8% and 13.1%, respectively.
A study published in the Tobacco Control academic journal in 2021 estimates that the six countries of the Gulf Cooperation Council – Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates – incur smoking-related healthcare costs exceeding $14.3 billion. This was only in 2016 and nearly 75% of the total cost is borne by governments in medical expenses related to smoking-related illnesses. Among these six countries, Saudi Arabia with the largest population has the highest smoking-related economic cost, exceeding $6.3 billion.
Taking into consideration the influence of history and culture, we have carefully selected and developed innovative tobacco products that cater to the tastes and desires of consumers. Our company is committed to improving the quality of life for smokers by offering new tobacco products that aim to address the smoking epidemic," said Mike Khalil, President and Founder of MVG.
The e-cigarette market is projected to grow at a rate of 9.7% annually, reaching $485 million by 2025, up from $267.9 million in 2018. The expected growth is attributed to the increasing number of young people and the influence of the media and e-cigarette companies. "Our goal as a company is to contribute to the growth of the e-cigarette market through innovation, brand recognition, and our harm reduction plan," said Mr. Halil.
The government can play a key role in changing people's smoking behavior. It must regulate and supervise the e-cigarette industry in each country, while the health sector should protect both the e-cigarette industry and consumers by ensuring their safety and integrity. Additionally, healthcare providers should advise smoking patients to transition to less harmful alternatives, such as e-cigarettes, through healthcare strategies and disease prevention plans. Mr. Halleul concluded.
Statement
This article is based on compiled information from a third party, and is intended for industry-related communication and learning purposes only.
This article does not represent the view of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity or accuracy of the content. The translation of this article is only for internal communication and research within the industry.
Due to limitations in our translation abilities, the translated article may not fully capture the intended meaning of the original. Please refer to the original text for accuracy.
2FIRSTS maintains complete alignment with the Chinese government with regard to any domestic, Hong Kong-Macau-Taiwan-related, or foreign-related statements and positions.
The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us to have it removed.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
